RxDoctor Payments Data

Jonathan Schreiber, MD

Gastroenterology · Baltimore, MDNPI 1245344282

Payments from drug & device makers

$2,285in general payments, 2019–2025

Across 115 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$716
  • Pfizer$199
  • Johnson & Johnson$184
  • Ferring Pharmaceuticals Inc.$162
  • Braintree Laboratories, Inc.$153
  • Ironwood Pharmaceuticals, Inc$136
  • plus $734 from 15 others
$1,400in research payments, 2019–2025

Across 1 payment — averaging $1400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$1K

What the payments were for

  • Food & beverage$2,16095%
  • Gifts$1255%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,285 in reported general payments places this provider in the 40th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$131,934
Medicare patients
530
Services billed
888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide66$84,272
ZenpepLipase/Protease/Amylase14$52,778
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates149$8,646
Omeprazole232$5,226
ClenpiqSod Picosulf/Mag Ox/Citric Ac30$5,095
Famotidine95$2,319
Esomeprazole Magnesium14$1,915
Dicyclomine Hcl67$1,656
CholestyramineCholestyramine (With Sugar)23$1,113
Pantoprazole Sodium65$984
Sucralfate21$527
Amitriptyline Hcl12$170
Mirtazapine13$164
Lactulose21$144
Metoclopramide Hcl12$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$716$84,27266 claims
Aimmune Therapeutics, Inc.Zenpep$28$52,77814 claims
Ferring Pharmaceuticals Inc.Clenpiq$162$5,09530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →